We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike (NKE - Free Report) , Eli Lilly (LLY - Free Report) and NVIDIA (NVDA - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Nike’s shares have outperformed the Zacks Shoes and Retail Apparel industry over the last three months (+2.7% vs. +1.6%), driven by strength in international business and the global NIKE Direct business which has been aiding its quarterly performance. Notably, the company delivered top- and bottom-line beat in third-quarter fiscal 2018 which also marked the 23rd straight earnings beat.
Third-quarter results reflected significant progress on the Consumer Direct Offense, positioning it for strong profitable growth in the future. Nike closed the third quarter with expectations of a trend reversal in its North America business in the fourth quarter, backed by the introduction of new innovation platforms and differentiated customer experiences in the marketplace.
Consequently, it provided robust guidance for fourth-quarter fiscal 2018 and initial view for fiscal 2019. However, its higher SG&A expenses are likely to continue hurting results in the fourth quarter.
Shares of Buy-rated Eli Lilly have underperformed the Zacks Large-Cap Pharmaceuticals industry in the last one year (-11.2% vs. +2.8%). However, the Zacks analyst thinks Lilly’s presence across a wide range of therapeutic areas provides support in the face of generic competition. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018.
Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. The decision to sell or spin-off the Animal Health segment, which has underperformed in 2017, is a prudent decision in our view. Also, competitive pressure on Lilly’s drugs is expected to rise this year.
Meanwhile, challenges remain for the company in the form of loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018.
Strong Buy-rated NVIDIA’s shares have surged in the last year, gaining in excess of +115.2% versus the Zacks General Semiconductor industry’s +53.8% gain, thanks to the company’s positive record of earnings surprises in the recent quarters. The Zacks analyst thinks NVIDIA’s sustained efforts toward attaining robust position in several emerging industries such as Artificial Intelligence (AI), deep learning and driverless cars industry have improved its growth prospects.
NVIDIA’s innovative product pipeline and strength in gaming and high-end notebook GPUs remain the positives. The company’s focus on GRID platforms can increase GPU adoption in data centers, giving it an advantage against its competitors.
Other noteworthy reports we are featuring today include Baxter (BAX - Free Report) , L Brands and Alleghany .
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Analyst Reports for Nike, Eli Lilly & NVIDIA
Monday, March 26, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike (NKE - Free Report) , Eli Lilly (LLY - Free Report) and NVIDIA (NVDA - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Nike’s shares have outperformed the Zacks Shoes and Retail Apparel industry over the last three months (+2.7% vs. +1.6%), driven by strength in international business and the global NIKE Direct business which has been aiding its quarterly performance. Notably, the company delivered top- and bottom-line beat in third-quarter fiscal 2018 which also marked the 23rd straight earnings beat.
Third-quarter results reflected significant progress on the Consumer Direct Offense, positioning it for strong profitable growth in the future. Nike closed the third quarter with expectations of a trend reversal in its North America business in the fourth quarter, backed by the introduction of new innovation platforms and differentiated customer experiences in the marketplace.
Consequently, it provided robust guidance for fourth-quarter fiscal 2018 and initial view for fiscal 2019. However, its higher SG&A expenses are likely to continue hurting results in the fourth quarter.
(You can read the full research report on Nike here >>>).
Shares of Buy-rated Eli Lilly have underperformed the Zacks Large-Cap Pharmaceuticals industry in the last one year (-11.2% vs. +2.8%). However, the Zacks analyst thinks Lilly’s presence across a wide range of therapeutic areas provides support in the face of generic competition. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018.
Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. The decision to sell or spin-off the Animal Health segment, which has underperformed in 2017, is a prudent decision in our view. Also, competitive pressure on Lilly’s drugs is expected to rise this year.
Meanwhile, challenges remain for the company in the form of loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018.
(You can read the full research report on Eli Lilly here >>>).
Strong Buy-rated NVIDIA’s shares have surged in the last year, gaining in excess of +115.2% versus the Zacks General Semiconductor industry’s +53.8% gain, thanks to the company’s positive record of earnings surprises in the recent quarters. The Zacks analyst thinks NVIDIA’s sustained efforts toward attaining robust position in several emerging industries such as Artificial Intelligence (AI), deep learning and driverless cars industry have improved its growth prospects.
NVIDIA’s innovative product pipeline and strength in gaming and high-end notebook GPUs remain the positives. The company’s focus on GRID platforms can increase GPU adoption in data centers, giving it an advantage against its competitors.
(You can read the full research report on NVIDIA here >>>).
Other noteworthy reports we are featuring today include Baxter (BAX - Free Report) , L Brands and Alleghany .
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>